PIPELINE WATCH – Nine Approvals, Two Filings And One Orphan Drug Designation
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.